Present disclosure relates generally to treating cancer such as spongioblastoma and non-Hodgkin lymphoma or in which subject suffer from advanced solid tumor other cancers composition and method, including application Bu Luomo structural domains and additional terminal protein (bromodomain and extra-terminal protein) (BET) inhibitor and direct at least one chemotherapeutics of inhibition BET. Compared with applying individual BET inhibitor or chemotherapeutics, BET inhibitor/chemotherapeutic agent combination therapy can produce synergistic effect, to improve the validity for the treatment of of cancer.
